Recent Press Releases

IMS Health Study Forecasts Global Spending on Medicines to Increase 30 Percent by 2018, to $1.3 Trillion

Spike in Growth in 2014-15 Driven by Innovation Surge and Few Patent Expiries PARSIPPANY, NJ, November 20, 2014 – More specialty drug innovation, greater patient access to medicines and reduced...

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults

TITUSVILLE, N.J., Nov.

Shire to Relocate Over 500 Jobs to Massachusetts

Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases Presence in Chesterbrook, Pa. Interim CFO Appointed Lexington, Mass., November 19, 2014 – Shire plc (LSE: SHP,...

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

American Heart Association's Scientific Sessions 2014: Latest real-world data once again reinforce benefits from Pradaxa®1,2 Two new analyses involving over 60,000 US patients in total...

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

Idarucizumab, which was granted Breakthrough Therapy Designation by the FDA, was shown to restore the blood clotting mechanism in healthy volunteers1,2 This is the first time that such an effect...

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent

THOUSAND OAKS, Calif.

Zoetis Announces Authorization of $500 Million Share Repurchase Program

Zoetis Announces Authorization of $500 Million Share Repurchase Program FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Zoetis Inc.(ZTS), the world's leading animal health company, today announced that its...

European Commission Grants Marketing Authorization for Gilead's Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

-- Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis -- FOSTER CITY,...

ASTRAZENECA STRATEGY ON TRACK TO DELIVER SUSTAINABLE GROWTH AND VALUE THROUGH INNOVATION

Late-stage pipeline transformed well ahead of plan through increased R&D productivity, accelerated programmes and targeted business development; 14 potential new medicines in Phase III or...

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

- Jardiance® (empagliflozin) data results presented at the 2014 Scientific Sessions of the American Heart Association

RIDGEFIELD, Conn.

People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes

New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital

ABBOTT PARK, Ill.,

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite...

Zoetis to Purchase Assets of Abbott Animal Health

$255 million deal expands Zoetis companion animal product portfolio to bring veterinarians solutions for pain, diabetes and oncology Transaction furthers Zoetis' bolt-on acquisition strategy...

Valeant Comments On Allergan Announcement

LAVAL, Quebec, Nov. 17, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE:...

Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue

-Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares - - Fastest Growing, Most Dynamic Pharmaceutical Company in Global Healthcare - - Leading Blockbuster...

Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

Data are Embargoed by American Heart Association until 10:45 AM CT Today Monday, November 17, 2014 8:30 am EST WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the...

2014 Access to Medicine Index – More being done, but progress is uneven

17 November 2014 | The world's leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations...